Update on Value-Based Medicine
Authors:
- Melissa M. BrownMBMelissa M. Brown
- Gary C. BrownGBGary C. Brown
- 1 May 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 24 (3) , 183-189
Abstract
To update concepts in Value-Based Medicine, especially in view of the Patient Protection and Affordable Care Act. The Patient Protection and Affordable Care Act assures that some variant of Value-Based Medicine cost-utility analysis will play a key role in the healthcare system. It identifies the highest quality care, thereby maximizing the most efficacious use of healthcare resources and empowering patients and physicians.Standardization is critical for the creation and acceptance of a Value-Based Medicine, cost-utility analysis, information system, since 27 million different input variants can go into a cost-utility analysis. Key among such standards is the use of patient preferences (utilities), as patients best understand the quality of life associated with their health states. The inclusion of societal costs, versus direct medical costs alone, demonstrates that medical interventions are more cost effective and, in many instances, provide a net financial return-on-investment to society referent to the direct medical costs expended. Value-Based Medicine provides a standardized methodology, integrating critical, patient, quality-of-life preferences, and societal costs, to allow the highest quality, most cost-effective care. Central to Value-Based Medicine is the concept that all patients deserve the interventions that provide the greatest patient value (improvement in quality of life and/or length of life).Keywords
This publication has 13 references indexed in Scilit:
- Changes in quality of life in visually impaired patients after low-vision rehabilitationInternational Journal of Rehabilitation Research, 2013
- Improved Vision-Related Function after Ranibizumab for Macular Edema after Retinal Vein OcclusionOphthalmology, 2012
- Preference-based comparative effectiveness and cost–effectivenessCurrent Opinion in Ophthalmology, 2012
- Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routineBritish Journal of Ophthalmology, 2012
- The power of hope: being a doctor is more than relying solely on the numbersBritish Journal of Ophthalmology, 2008
- The effect of comorbidities upon ocular and systemic health-related quality of lifeBritish Journal of Ophthalmology, 2008
- Health Care Economic Analyses and Value-Based MedicineSurvey of Ophthalmology, 2003
- Quality of life with macular degeneration: perceptions of patients, clinicians, and community membersBritish Journal of Ophthalmology, 2003
- Validity of the time trade-off and standard gamble methods of utility assessment in retinal patientsBritish Journal of Ophthalmology, 2002
- Quality of Life With Visual Acuity Loss From Diabetic Retinopathy and Age-Related Macular DegenerationArchives of Ophthalmology (1950), 2002